This review summarizes emerging hematological targets and therapies for atherosclerotic cardiovascular disease.
Answers are grounded in this paper and cite their sources.
Identifies emerging hematological targets for ASCVD; leaves open clinical translation pending prospective trials.
Atherosclerotic cardiovascular disease is the leading cause of death and a major part of its pathophysiology remains obscure. Some hematological targets have been related to the development and clinical outcome of this disease, especially soluble cytokines, leukocytes, red blood cells, hemostatic factors and platelets, and bone-marrow vascular progenitors. These emerging factors may be modulated by current antiatherosclerotic pharmacotherapy, target-designed novel drugs or progenitor cell therapy. The aim of current review article is to comprehensively review the role of these antiatherosclerotic targets and therapy.
No takes yet. Share an insight, caveat, or question.
Santiago Redondo (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: